Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -19.35%, near the high end of its 5-year range (-1079.00%–0.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-19.35%
NET PROFIT MARGIN AVG 10Y
-4.59%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Market Cap
$65.87M
Net Profit Margin
-235.00%
TTM Avg
-200.38%
3Y Avg
-100.19%
5Y Avg
-66.80%
Market Cap
$67.52M
Net Profit Margin
-33044.00%
TTM Avg
-18819.13%
3Y Avg
-12177.01%
5Y Avg
-8726.92%
Market Cap
$64.18M
Net Profit Margin
-41.36%
TTM Avg
-52.43%
3Y Avg
-63.29%
5Y Avg
-45.57%
Market Cap
$63.78M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2871.11%
5Y Avg
-2144.71%
Market Cap
$68.10M
Net Profit Margin
163.32%
TTM Avg
-34.49%
3Y Avg
-63.76%
5Y Avg
-75.19%
Market Cap
$63.02M
Net Profit Margin
-13.72%
TTM Avg
-20.80%
3Y Avg
-11.88%
5Y Avg
-17.10%
Market Cap
$68.90M
Net Profit Margin
17.18%
TTM Avg
-64.27%
3Y Avg
-50.52%
5Y Avg
-660.79%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XBiotech Inc. (XBIT) | $65.85M | 0.00% | 0.00% | 0.00% | -19.35% |
| Cingulate Inc. (CING)vs › | $65.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -235.00% | -200.38% | -100.19% | -66.80% |
| iBio, Inc. (IBIO)vs › | $67.52M | -33044.00% | -18819.13% | -12177.01% | -8726.92% |
| Alps Group Inc (ALPS)vs › | $64.18M | -41.36% | -52.43% | -63.29% | -45.57% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | 0.00% | 0.00% | -2871.11% | -2144.71% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 163.32% | -34.49% | -63.76% | -75.19% |
| InterCure Ltd. (INCR)vs › | $63.02M | -13.72% | -20.80% | -11.88% | -17.10% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 17.18% | -64.27% | -50.52% | -660.79% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -22.52% | -11.22% | -69.63% | -131.75% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -1067.67% |
| 2022-09-30 | -753.45% |
| 2022-06-30 | -761.05% |
| 2022-03-31 | -1079.00% |
| 2021-12-31 | -143.71% |
| 2021-09-30 | -72.16% |
| 2021-06-30 | -113.10% |
| 2021-03-31 | -52.95% |
| 2020-12-31 | -34.88% |
| 2020-09-30 | -23.95% |
| 2020-06-30 | -44.16% |
| 2020-03-31 | -0.11% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-11-02 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
